SCHEMBL18779308

SCHEMBL18779308

Cc1cnc(CN2C(=O)CN(C)C2=O)nc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.47
PLA2G7 Q13093 1/20 0.45
HDAC6 Q9UBN7 1/20 0.37
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PIM1 P11309 2/20 0.35
CYP1A2 P05177 3/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
GRM2 Q14416 2/20 0.34
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
ADK P55263 1/20 0.33
SLC2A1 P11166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17133460 0.87 NTRK1 (0.47) NTRK1PLA2G7HDAC6ALDH1A1MEN1
Hydrochloric Acid SCHEMBL18762402 0.86 NTRK1 (0.46) NTRK1PLA2G7HDAC6ALDH1A1MEN1
SCHEMBL17111597 0.85 NTRK1 (0.59) NTRK1PLA2G7HDAC6
SCHEMBL18779326 0.84 NTRK1 (0.43) NTRK1ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL17133458 0.77 NTRK1 (0.56) NTRK1PLA2G7
SCHEMBL11650145 0.70 HDAC6 (0.60) PLA2G7HDAC6ALDH1A1MEN1KMT2A
SCHEMBL10271772 0.70 PDE10A (0.43) NTRK1ALDH1A1MEN1KMT2ACASP1
SCHEMBL18779331 0.69 NTRK1 (0.47) NTRK1ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL20067097 0.69 PDE10A (0.42) NTRK1ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL18779312 0.69 PDE10A (0.42) NTRK1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815846-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2017-11-14 US disclosed
US-20170114071-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2017-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114071-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF NGFR, NGF, NTRK1 NTRK1 3/4885PLA2G7 791/4885HDAC6 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.